CHARLES RIVER LABORATORIES ANNOUNCES PLANNED OFFERING OF $1

RIVER LABORATORIES ANNOUNCES PLANNED OFFERING

OF $1 BILLION OF SENIOR NOTES

WILMINGTON, Mass., March 8,

2021 - Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it intends to offer $1 billion

aggregate principal amount of senior notes due 2029 and 2031 (the "notes") in an unregistered offering, subject to

Charles River intends to use

the gross proceeds of the offering of the notes to redeem its 5.5% senior notes due 2026 (the "2026 notes"), to fund,

along with borrowings under its senior credit facilities, a portion of the purchase price for its proposed acquisition of Cognate

BioServices, Inc., and to pay fees and expenses in connection with the offering, the redemption of the 2026 notes, and the amendment

of its senior credit facilities.

The notes have not been, and

will not be, registered under the Securities Act of 1933, as amended (the "Securities Act"), or under the securities

laws of any other jurisdiction. Unless they are registered, the notes may be offered only in transactions that are exempt from

registration under the Securities Act and applicable state securities laws. The notes will be offered only to persons reasonably

believed to be qualified institutional buyers under Rule 144A under the Securities Act and to non-U.S. persons outside the United

States under Regulation S of the Securities Act.

This press release does not constitute

an offer to sell or a solicitation of an offer to buy the notes, nor shall there be any sale of the notes in any state or jurisdiction

in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws

of any such jurisdiction.

Caution Concerning Forward-Looking

This news release includes forward-looking

statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified

by the use of words such as "anticipate," "believe," "expect," "will," "may,"

"estimate," "plan," "outlook," and "project" and other similar expressions that

predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements include

statements in this news release regarding the potential securities offering and our expectations regarding the redemption of 5.5%

senior notes due 2016 or the payment of a portion of the purchase price for the proposed acquisition of Cognate BioServices, Inc.

with the proceeds of the notes offering. Forward-looking statements are based on Charles River's current expectations and

beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to

differ materially from those stated or implied by the forward-looking statements. A further description of these risks, uncertainties,

and other matters can be found in the Risk Factors detailed in Charles River's Annual Report on Form 10-K as filed on February

17, 2021, as well as other filings we make with the Securities and Exchange Commission. Because forward-looking statements involve

risks and uncertainties, actual results and events may differ materially from results and events currently expected by Charles

River, and Charles River assumes no obligation and expressly disclaims any duty to update information contained in this news release

except as required by law.

River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading

academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are

focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe

manufacture of new therapies for the patients who need them.